{
    "clinical_study": {
        "@rank": "4812", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (enhanced standard care)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding gynecologic cancer treatments and sexuality, and provision of a SCP created using OncoLink over 1 hour following baseline assessment and before 6 months."
            }, 
            {
                "arm_group_label": "Arm II (psychological intervention)", 
                "arm_group_type": "Experimental", 
                "description": "Patients participate in individual or group therapy over 1.5 hours weekly for 4 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well psychosexual intervention works in patients\n      with stage I-III gynecologic cancer. Psychosexual intervention may improve sexual and\n      psychosocial function."
        }, 
        "brief_title": "Psychosexual Intervention in Patients With Stage I-III Gynecologic Cancer", 
        "condition": [
            "Leydig Cell Tumor", 
            "Ovarian Sarcoma", 
            "Ovarian Stromal Cancer", 
            "Stage I Gestational Trophoblastic Tumor", 
            "Stage I Uterine Sarcoma", 
            "Stage I Vaginal Cancer", 
            "Stage I Vulvar Cancer", 
            "Stage IA Cervical Cancer", 
            "Stage IA Endometrial Carcinoma", 
            "Stage IA Fallopian Tube Cancer", 
            "Stage IA Ovarian Epithelial Cancer", 
            "Stage IA Ovarian Germ Cell Tumor", 
            "Stage IA Primary Peritoneal Cavity Cancer", 
            "Stage IB Cervical Cancer", 
            "Stage IB Endometrial Carcinoma", 
            "Stage IB Fallopian Tube Cancer", 
            "Stage IB Ovarian Epithelial Cancer", 
            "Stage IB Ovarian Germ Cell Tumor", 
            "Stage IB Primary Peritoneal Cavity Cancer", 
            "Stage IC Fallopian Tube Cancer", 
            "Stage IC Ovarian Epithelial Cancer", 
            "Stage IC Ovarian Germ Cell Tumor", 
            "Stage IC Primary Peritoneal Cavity Cancer", 
            "Stage II Endometrial Carcinoma", 
            "Stage II Gestational Trophoblastic Tumor", 
            "Stage II Uterine Sarcoma", 
            "Stage II Vaginal Cancer", 
            "Stage II Vulvar Cancer", 
            "Stage IIA Cervical Cancer", 
            "Stage IIA Fallopian Tube Cancer", 
            "Stage IIA Ovarian Epithelial Cancer", 
            "Stage IIA Ovarian Germ Cell Tumor", 
            "Stage IIA Primary Peritoneal Cavity Cancer", 
            "Stage IIB Cervical Cancer", 
            "Stage IIB Fallopian Tube Cancer", 
            "Stage IIB Ovarian Epithelial Cancer", 
            "Stage IIB Ovarian Germ Cell Tumor", 
            "Stage IIB Primary Peritoneal Cavity Cancer", 
            "Stage IIC Fallopian Tube Cancer", 
            "Stage IIC Ovarian Epithelial Cancer", 
            "Stage IIC Ovarian Germ Cell Tumor", 
            "Stage IIC Primary Peritoneal Cavity Cancer", 
            "Stage III Gestational Trophoblastic Tumor", 
            "Stage III Uterine Sarcoma", 
            "Stage III Vaginal Cancer", 
            "Stage III Vulvar Cancer", 
            "Stage IIIA Cervical Cancer", 
            "Stage IIIA Endometrial Carcinoma", 
            "Stage IIIA Fallopian Tube Cancer", 
            "Stage IIIA Ovarian Epithelial Cancer", 
            "Stage IIIA Ovarian Germ Cell Tumor", 
            "Stage IIIA Primary Peritoneal Cavity Cancer", 
            "Stage IIIB Cervical Cancer", 
            "Stage IIIB Endometrial Carcinoma", 
            "Stage IIIB Fallopian Tube Cancer", 
            "Stage IIIB Ovarian Epithelial Cancer", 
            "Stage IIIB Ovarian Germ Cell Tumor", 
            "Stage IIIB Primary Peritoneal Cavity Cancer", 
            "Stage IIIC Endometrial Carcinoma", 
            "Stage IIIC Fallopian Tube Cancer", 
            "Stage IIIC Ovarian Epithelial Cancer", 
            "Stage IIIC Ovarian Germ Cell Tumor", 
            "Stage IIIC Primary Peritoneal Cavity Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Uterine Cervical Neoplasms", 
                "Leydig Cell Tumor", 
                "Trophoblastic Neoplasms", 
                "Vaginal Neoplasms", 
                "Vulvar Neoplasms", 
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal", 
                "Germinoma", 
                "Ovarian Neoplasms", 
                "Endometrial Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Gestational Trophoblastic Neoplasms", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Efficacy for reducing the severity of sexual distress, difficulty, and dysfunction in a\n      phase II randomized clinical trial (RCT).\n\n      OUTLINE: Patients are randomized to 1 of 2 arms.\n\n      ARM I (Enhanced standard care): Patients participate in enhanced standard care intervention\n      comprising stress reduction, information delivery regarding gynecologic cancer treatments\n      and sexuality, and provision of a survivorship care plan (SCP) created using OncoLink over 1\n      hour following baseline assessment and before 6 months.\n\n      ARM II (Psychological intervention): Patients participate in individual or group therapy\n      over 1.5 hours weekly for 4 weeks, bi-weekly for 8 weeks, and monthly for 2 months and\n      complete assessment interviews.\n\n      After completion of study treatment, patients are followed up at 3, 6, and 9 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stage I-III gynecologic cancer (any site)\n\n          -  Current heterosexual or lesbian sexual partner\n\n          -  Able to speak/read English\n\n          -  Able to give informed consent\n\n        Exclusion Criteria:\n\n          -  Prior non-gynecologic cancer diagnosis\n\n          -  Refusal of any cancer treatment(s)\n\n          -  Non-ambulatory\n\n          -  Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or\n             significant sensory deficit\n\n          -  Major mental illness (e.g, schizophrenia, major depressive disorder)\n\n          -  Current selective serotonin reuptake inhibitor (SSRI) use\n\n          -  Current/recent (prior 12 months) pregnancy\n\n          -  Residence > 70 miles from research site"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764802", 
            "org_study_id": "OSU-10077", 
            "secondary_id": [
                "NCI-2012-01341", 
                "1R21CA149675-01A1"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm I (enhanced standard care)", 
                    "Arm II (psychological intervention)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm I (enhanced standard care)", 
                    "Arm II (psychological intervention)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }, 
            {
                "arm_group_label": "Arm I (enhanced standard care)", 
                "description": "Participate in enhanced standard care", 
                "intervention_name": "behavioral, psychological or informational intervention", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm II (psychological intervention)", 
                "description": "Participate in psychological intervention", 
                "intervention_name": "behavioral, psychological or informational intervention", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Psychosexual Intervention", 
            "Cancer", 
            "Gynecologic Cancer Patients"
        ], 
        "lastchanged_date": "July 26, 2013", 
        "link": {
            "description": "Jamesline", 
            "url": "http://cancer.osu.edu"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43210"
                }, 
                "name": "Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Psychosexual Intervention for Gynecologic Cancer Patients", 
        "overall_official": {
            "affiliation": "Ohio State University Comprehensive Cancer Center", 
            "last_name": "Barbara Andersen", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Multilevel modeling will be used to model time effects compared to repeated-measures analysis of variance (ANOVA) because it allows not only fitting different patterns of average change (i.e., linear, quadratic), but also estimates individual variability in the rate of change. Both linear and quadratic change models will be tested and an optimal model will be determined. 95% confidence intervals will be obtained.", 
                "measure": "Sexual behavior/repertoire (kissing, intercourse, etc.) graded using the Sexual Experiences Scale (SES)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 months"
            }, 
            {
                "description": "Principal components analysis yields six subscales: desire, arousal, lubrication, orgasm, satisfaction, and pain. Items are rated using the Likert scales. 95% confidence intervals will be obtained.", 
                "measure": "Sexual responsiveness (desire, arousal, orgasm) using the Female Sexual Functioning Index (FSFI)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "95% confidence intervals will be obtained.", 
                "measure": "Sexual satisfaction graded using the global evaluation from the Derogatis Sexual Function Inventory (DSFI)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 months"
            }, 
            {
                "description": "The Likert scale will be used. 95% confidence intervals will be obtained.", 
                "measure": "Sexual distress graded using the female Sexual Distress Scale (FSDS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "measure": "Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764802"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ohio State University Comprehensive Cancer Center", 
            "investigator_full_name": "Barbara Andersen", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The Likert scale will be used. 95% confidence intervals will be obtained.", 
                "measure": "Emotional distress graded using the Profile of Mood States (POMS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 months"
            }, 
            {
                "description": "The Likert scale will be used. 95% confidence intervals will be obtained.", 
                "measure": "Depressive symptoms graded using the Center for Epidemiologic Studies Depression Scale (CES-D)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 months"
            }, 
            {
                "description": "The eight primary subscales are summarized into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).", 
                "measure": "Health-related quality of life graded according to the RAND Medical Outcomes Study, Short-form 12 (SF-12)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 months"
            }, 
            {
                "measure": "Cancer-related stress graded according to the Impact of Events Scale-Revised (IES-R)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 months"
            }, 
            {
                "measure": "Body change stress graded according to the Impact of Treatment Scale (ITS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 months"
            }
        ], 
        "source": "Ohio State University Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Ohio State University Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}